PT98890A - Processo para a preparacao de composicoes farmaceuticas antiemeticas contendo uma mistura de ondansetron com um agente antiemetico ou tranquilizante - Google Patents

Processo para a preparacao de composicoes farmaceuticas antiemeticas contendo uma mistura de ondansetron com um agente antiemetico ou tranquilizante Download PDF

Info

Publication number
PT98890A
PT98890A PT98890A PT9889091A PT98890A PT 98890 A PT98890 A PT 98890A PT 98890 A PT98890 A PT 98890A PT 9889091 A PT9889091 A PT 9889091A PT 98890 A PT98890 A PT 98890A
Authority
PT
Portugal
Prior art keywords
dosage form
ondansetron
compound selected
antiemetic
group
Prior art date
Application number
PT98890A
Other languages
English (en)
Inventor
Francisco Jao
Hoa T Huynh
Patrick S L Wong
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24319368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT98890(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of PT98890A publication Critical patent/PT98890A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (1)

  1. 28 fí REIVINDICAÇÕES: la. - Processo para a preparação de uma composição farmacêutica antiemética para a diminuição dos vómitos e nauseas em seres humanos, caracterizado pelo facto de se misturar de preferência entre cerca de lmg e 200 mg de ondansetron com entre cerca de 1 e 200 mg de pelo menos um composto escolhido do grupo formado por benzamina, butirofenona, fenotiazina, corticosteróides, benzodrazipina e canabionóides, e eventualmente com as substancias veiculares farmaceuticamente apropriadas e se conferir à mistura, uma forma de dosagem específica. 2a. - Processo de acordo com a reivindicação 1, caracterizado pelo facto de se misturar 1 a 200 mg de ondansetron com 1 a 200 mg de pelo menos um composto escolhido do grupo formado por metoclopramida, haloperidol, droperidol, procloroperazina, cloropromazina, dexametasone, metilprednisolone, horazepam e nabilone. 3a. - Forma de dosagem para administrar uma composição farmacêutica antiemética e antinausea a um paciente, caracterizada pelo facto de compreender (a) uma parede que envolve um compartimento; (b) uma composição colocada dentro do compartimento compreendendo entre 1 a 400 mg de ondansetron e de fármaco antiemético e antinausea; r ο
    ο (c) uma composição colocada dentro do compartimento, que compreende um polímero que se expande na presença de fluido que penetra no compartimento; e (d) pelo menos um orifício de saída na parede, que liga o exterior com o interior da forma de dosagem para administrar os ingredientes activos ao paciente. 4a. - Forma de dosagem para administrar um fármaco antiemético e antináusea de acordo com a reivindicação 3, caracterizada pelo facto de o compartimento conter adicionalmente pelo menos um composto escolhido do grupo formado por benzamina, butirofenona, fenotiazina, corticosteróide, benzodrazipina e um canabionóide. 5a. - Forma de dosagem para administrar um fármaco antiemético e antináusea de acordo com a reivindicação 3, caracterizada pelo facto de conter adicionalmente pelo menos um composto seleccionado do grupo formado por metoclopramida, haloperidol, droperidol, procloroperzina, cloropromazina, dexametasona, metilprednisolona, horazepam, nabilone e dronoabinol. Lisboa, 6 de Setembro de 1991 J0 Agente Oficial da Propriedade Industrial Ά Γ’> AMÉRICO DA SILVA CARVALHO Agente Oficial de PrrpfituLiL l· lltrial Ruo KAsrauês de F -"i •rs. Ki0 127 -Z“ 1000 LISBOA
PT98890A 1990-09-10 1991-09-06 Processo para a preparacao de composicoes farmaceuticas antiemeticas contendo uma mistura de ondansetron com um agente antiemetico ou tranquilizante PT98890A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/580,030 US5166145A (en) 1990-09-10 1990-09-10 Antiemetic therapy

Publications (1)

Publication Number Publication Date
PT98890A true PT98890A (pt) 1992-07-31

Family

ID=24319368

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98890A PT98890A (pt) 1990-09-10 1991-09-06 Processo para a preparacao de composicoes farmaceuticas antiemeticas contendo uma mistura de ondansetron com um agente antiemetico ou tranquilizante

Country Status (7)

Country Link
US (2) US5166145A (pt)
AU (1) AU8536691A (pt)
IE (1) IE913132A1 (pt)
MX (1) MX9100970A (pt)
PT (1) PT98890A (pt)
WO (1) WO1992004012A1 (pt)
ZA (1) ZA917106B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219538A (en) * 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5766939A (en) * 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
IL94183A (en) 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
GB2290963A (en) * 1994-06-28 1996-01-17 Kenneth Francis Prendergast Pharmaceutical uses of ondansetron
US5661142A (en) * 1996-04-17 1997-08-26 Naeger; David M. Anti-emetic composition
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DK0946151T3 (da) * 1996-11-25 2006-08-28 Alza Corp Doseringsform med stigende dosisfrigivelse
EP1782798A3 (en) 1996-11-25 2008-05-21 Alza Corporation Ascending-dose dosage form
ZA979605B (en) * 1996-11-25 1998-05-21 Alza Corp Ascending-dose dosage form.
AU745361B2 (en) * 1997-04-18 2002-03-21 Janssen Pharmaceutica N.V. Use of 5HT3 antagonists for promoting intestinal lavage
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
ES2293875T3 (es) * 1997-10-01 2008-04-01 Novadel Pharma Inc. Aerosol bucal no polar.
US5981552A (en) * 1998-10-23 1999-11-09 Taylor Pharmaceuticals Sublingual and buccal compositions of droperidol and method for treating migraine
US5997884A (en) * 1998-02-12 1999-12-07 Taylor Pharmaceuticals Compositions and method for treating migraine
US5990134A (en) * 1998-08-12 1999-11-23 Taylor Pharmaceuticals Oral droperidol compositions and method for treating migraine
AU2599699A (en) * 1998-02-12 1999-08-30 Taylor Pharmaceuticals Droperidol compositions and method for using same
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2438097C (en) * 2001-02-14 2006-04-25 Gw Pharma Limited Cannabinoids pharmaceutical formulations
WO2003092591A2 (en) * 2002-04-30 2003-11-13 Npd Llc Multi-phasic delivery via transmucosal absorption of antiemetic medicaments
US6673792B1 (en) * 2002-07-11 2004-01-06 Upchuck, Llc Broad-spectrum anti-emetic compositions and associated methods
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
WO2005030182A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
WO2006017351A1 (en) * 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20060263421A1 (en) * 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
BRPI0811430A2 (pt) * 2007-05-10 2015-06-23 Novadel Pharma Inc Composições anti-insônia e processos
MX2010001242A (es) * 2007-07-30 2010-07-02 Alltranz Inc Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US20110092493A1 (en) * 2008-09-24 2011-04-21 Clark Levi Dose-controlled transdermal promethazine compositions and methods of use
EP3068376A4 (en) 2013-11-14 2017-06-07 Insys Pharma, Inc. Ondansetron sublingual spray formulation
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
EP0265061B1 (en) * 1986-09-18 1992-01-08 London School of Pharmacy Innovations Ltd Pharmaceutical formulation
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5032578A (en) * 1990-09-17 1991-07-16 E. R. Squibb & Sons, Inc. Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors

Also Published As

Publication number Publication date
US5166145A (en) 1992-11-24
WO1992004012A1 (en) 1992-03-19
ZA917106B (en) 1992-05-27
AU8536691A (en) 1992-03-30
MX9100970A (es) 1992-05-04
IE913132A1 (en) 1992-03-11
US5310561A (en) 1994-05-10

Similar Documents

Publication Publication Date Title
PT98890A (pt) Processo para a preparacao de composicoes farmaceuticas antiemeticas contendo uma mistura de ondansetron com um agente antiemetico ou tranquilizante
US10940205B2 (en) Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
DE2624025C2 (pt)
US5521166A (en) Antiprogestin cyclophasic hormonal regimen
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
BR9911073A (pt) Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma
BR9917403A (pt) Composições farmacêuticas orais contendo taxanos, e métodos de tratamento empregando as mesmas
DE2508615C2 (pt)
DE69227257T2 (de) Arzneimittel
KR870700018A (ko) 클로로플루오로카본 연무질 포사약 조성물을 함유하는 약제
KR970704422A (ko) 투여용 약제학적 조성물
JP2008526856A (ja) 活性ビタミンｄ化合物またはその模倣体による血栓性疾患の予防
BR0113539A (pt) Processo para a preparação de composições farmacêuticas para uso com formulações de gelatina macia
DE2638507A1 (de) Arzneimittel mit anabolischer wirksamkeit
BR0208012A (pt) Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
JP4510289B2 (ja) 筋萎縮性側索硬化症の治療薬を製造するためのイチョウ抽出物の使用
KR970061244A (ko) 치매 치료용 약학 조성물
CN108261408A (zh) 充液硬胶囊药物制剂
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
BRPI0513806A (pt) composição medicinal contendo remédio para diabetes
BR0111051A (pt) Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente
KR20010032716A (ko) 의약의 제조를 위한 은행 추출물의 용도
GEP20033046B (en) Parenteral Cisplatin Emulsion
EP0322020A1 (en) Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis
BR0306778A (pt) Derivados de carboxamidina e seu uso no tratamento de doenças vasculares

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19920326

FC3A Refusal

Effective date: 19981102